Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy.

Nearly 80% of patients with malignant uterine smooth muscle tumor will suffer local relapse and/or distant metastases after initial surgical resection. There is no convincing evidence that the addition of pelvic radiation improves the outcome. However, adjuvant chemotherapy might be an appropriate therapeutic modality.
Between 1986 and 1991, 13 consecutive patients with malignant uterine smooth muscle tumors were treated at Yale-New Haven Hospital with a combination chemotherapy containing etoposide 100 mg/M2 on days 1 and 2, cisplatin 50 mg/M2 on day 1, and doxorubicin 50 mg/M2 on day 1, repeated every 28 days. Six patients had Stage I disease, one patient had Stage III disease, and six patients had Stage IV disease. The number of cycles ranged from 2 to 9.
The median follow-up was 30 months (range 4-81). The mean overall survival for the group was 43.1 +/- 6.7 months, with the progression-free interval of 25.5 +/- 8.0 months. Of the seven patients with evaluable disease, one patient had complete response and one had partial response (total response rate of 28.6%). Of the six patients treated adjuvantly, three recurred at 9, 33, and 59 months (recurrence rate of 50%).
We conclude that this combination has only modest activity against malignant uterine smooth muscle tumors at the schedule and doses tested.
AuthorsE Resnik, S K Chambers, M L Carcangiu, E I Kohorn, P E Schwartz, I T Chambers
JournalJournal of surgical oncology (J Surg Oncol) Vol. 63 Issue 3 Pg. 145-7 (Nov 1996) ISSN: 0022-4790 [Print] UNITED STATES
PMID8944057 (Publication Type: Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents, Phytogenic
  • Etoposide
  • Doxorubicin
  • Cisplatin
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage)
  • Antineoplastic Agents, Phytogenic (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cisplatin (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Leiomyosarcoma (drug therapy)
  • Middle Aged
  • Myometrium
  • Neoplasms, Muscle Tissue (drug therapy, pathology)
  • Survival Analysis
  • Treatment Outcome
  • Uterine Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: